Type 17 CD8+ T cells display enhanced antitumor immunity.
Blood
; 114(3): 596-9, 2009 Jul 16.
Article
em En
| MEDLINE
| ID: mdl-19471017
ABSTRACT
Interleukin-17 (IL-17)-secreting CD8(+) T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8(+) T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17-producing CD8(+) T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-gamma-producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia Adotiva
/
Linfócitos T CD8-Positivos
/
Interleucina-17
/
Neoplasias Experimentais
Limite:
Animals
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article